HE prophylactic administration of indomethacin reduces the incidence of patent ductus arteriosus and severe intraventricular hemorrhage in very-low-birth-weight infants (those with birth weights below 1500 g). 1 Our current understanding of the mechanisms by which indomethacin prevents intraventricular hemorrhage is speculative 2 and indicates that a decrease in cerebral perfusion may be involved. 3, 4 Although such a decrease may provide protection against intraventricular hemorrhage, 4 it may also increase the risk of brain ischemia. 3 Knowledge about the effects of indomethacin prophylaxis on neurologic development is therefore crucial, but few data are available on its longer-term motor, sensory, and cognitive effects. 1 We undertook this study to determine whether the prophylactic administration of indomethacin improves survival without neurosensory impairment in extremely-low-birth-weight infants (those with birth weights below 1000 g). A secondary goal was to obtain additional information about the effects of indomethacin on the incidence of patent ductus arteriosus, pulmonary hemorrhage, chronic lung disease, necrotizing enterocolitis, intracranial abnormalities, and retinopathy.
METHODS

Study Infants
Infants with birth weights ranging from 500 to 999 g were considered for enrollment when they were two hours old. The criteria for exclusion are listed in Figure 1 . A history, a physical examination, and a platelet count were the only screening tests prescribed by the protocol. The research-ethics boards of all 32 participating clinical centers approved the protocol, and written informed consent was obtained from a parent or guardian of each infant. Investigational-new-drug applications were filed with Health Canada and the U.S. Food and Drug Administration because indomethacin is not approved for prophylactic administration in preterm infants in either country. Clinical-trial-notification applications were filed in Australia 
Randomization
A computer-generated randomization scheme was used to assign the infants (in random blocks of two or four) to treatment groups in a 1:1 ratio. Randomization was stratified according to birth weight (500 to 749 g vs. 750 to 999 g) and according to study center. Each study pharmacist received a binder containing the sequence of treatment-group assignments for each birth-weight stratum from a statistician at the coordinating center who was not otherwise involved in the trial. At each study center, access to the binder was restricted to selected pharmacy personnel.
Intervention
The infants received either indomethacin, 0.1 mg per kilogram of body weight (Indocid P.D.A., Merck Frosst, Kirkland, Que., Canada, and Merck, West Point, Pa.), or an equivalent volume of normal saline. Three doses were given at 24-hour intervals. Each dose was infused intravenously over a period of 20 minutes. Since even a small volume of reconstituted indomethacin has a slightly yellow tinge, all syringes were partially masked with yellow tape.
Primary Outcome
The primary outcome was death before a corrected age of 18 months or documentation in survivors of one or more of the following: cerebral palsy, cognitive delay, hearing loss requiring amplification, and bilateral blindness. Cerebral palsy was diagnosed if the child had nonprogressive motor impairment characterized by abnormal muscle tone and a decreased range or control of movements. Cognitive delay was defined as a Mental Development Index score of less than 70 (2 SD below the mean of 100) on the Bayley Scales of Infant Development II. 5 A score between 85 and 114 is classified as normal, and scores lower than 70 suggest that cog- 2756 Infants with a birth weightŁ of 500-999 g who survivedŁ for »2 hr were screened 981 Infants were excluded for the following reasons (more than one may apply): unable to administer study drug within 6 hr of birth (n=469) structural heart disease, renal disease, or both known or strongly suspectedŁ (n=24) dysmorphic features or congenital abnormalities likely to affect life expectancy or neurologic development or to be associated with structural heart disease or renal disease (n=49) maternal tocolytic therapy with indomethacin or another prostaglandin inhibi-Ł tor within 72 hr before delivery (n=245) overt clinical bleeding at more than one site (n=8) platelet count <50,000/mm 3 nitive development is markedly delayed. 5 The score was assumed to be less than 70 if the child could not be tested because of severe developmental delay. Audiometry was performed to determine the presence or absence of hearing loss. A central adjudication committee that was unaware of the group assignments reviewed the results of audiologic tests for all infants with potential deafness whose hearing had not been amplified. Blindness was defined as a corrected visual acuity of less than 20/200. A follow-up evaluation was targeted for a corrected age of 18 months, but the protocol allowed a window of 18 to 21 months (12 to 21 months for audiologic testing). Efforts to conduct assessments continued beyond a corrected age of 21 months in an attempt to ensure the completeness of the results. Home visits or assessments in facilities not participating in the study were permitted when necessary. Documentation of the composite primary outcome required confirmation that the infant had died or had survived with any one of the four types of impairment, and documentation of the absence of the primary outcome required confirmation that the infant had survived without any impairment. Since a single missing component of the follow-up assessment would result in a designation of "missing" for the primary outcome, the steering committee developed detailed a priori criteria to determine what constituted adequate evidence of the presence or absence of each component of the primary outcome. These criteria required an in-person assessment by an appropriate health professional and the completion of the psychometric assessment during or after the permissible time window. In cases in which it was difficult to obtain audiometric test results, deafness requiring amplification of hearing was assumed to be absent if there was no indication of hearing loss during the clinical examination and the Bayley test. This assumption was made in the cases of 27 children.
Secondary Outcomes
Hydrocephalus necessitating the placement of a shunt, seizure disorder, and microcephaly (a head circumference below the 3rd percentile for a reference population of normal children 6 ) were secondary long-term outcomes. While the infants were hospitalized in the neonatal intensive care unit, various short-term outcomes were assessed. Patent ductus arteriosus was diagnosed by echocardiography and Doppler flow studies, which were requested only when there was a clinical suspicion of the condition. Left-to-right ductal shunting had to be confirmed by echocardiography with Doppler flow before drug or surgical therapy to close the duct was undertaken. 7 Pulmonary hemorrhage was diagnosed if a bloodtinged tracheal aspirate was obtained. Chronic lung disease was defined by the need for supplemental oxygen at 36 weeks of postmenstrual age. 8 Cranial ultrasonography was recommended between the 5th and 8th days of life, between the 21st and 28th days, and between 34 and 36 weeks of postmenstrual age if the infant was still hospitalized in the study center at that time. The scans were read locally, and copies of the written reports were sent to the coordinating center. Hemorrhages were analyzed separately so that we could compare our results with those of previous investigators. Hemorrhages of grade 3 or 4 were considered severe. 9 Several types of lesions were considered as a group because they all indicate probable damage to the cerebral white matter 10 ; these included echodense intraparenchymal lesions, periventricular leukomalacia, porencephalic cysts, and ventriculomegaly with or without intraventricular hemorrhage. Necrotizing enterocolitis was diagnosed during surgery, at autopsy, or by a finding of pneumatosis intestinalis, hepatobiliary gas, or free intraperitoneal air on radiography. Retinopathy was diagnosed according to the international classification. 11, 12 Statistical Analysis All primary and secondary outcomes were dichotomous. Since randomization was stratified according to birth weight and study center, the analyses of outcomes were adjusted for these two factors with the use of a logistic-regression model 13 that included terms for treatment, birth-weight stratum, center (smaller centers were combined), and interactions between birth weight and center when appropriate. The regression coefficient associated with treatment in the fitted model yielded a point estimate and confidence interval for the treatment effect expressed as an odds ratio. The quotient of the estimated coefficient and its standard error was used as a z-test statistic for the null hypothesis of no treatment effect. Cumulative mortality was estimated with the Kaplan-Meier 13 method. All P values are two-sided and have not been adjusted for multiple testing.
An external safety monitoring committee reviewed the study data every four to six months during the enrollment phase. With the exception of this monitoring committee and the local study pharmacists, no one involved in the study or in the care and followup of the infants was aware of the treatment-group assignments.
RESULTS
Study Infants and Intervention
The numbers of infants who were eligible for the study, the numbers assigned to receive indomethacin or placebo, and the numbers for whom follow-up data were available are shown in Figure 1 . A total of 1202 infants were enrolled -505 in Canada; 384 in Australia, New Zealand, and Hong Kong; and 313 in the United States. The base-line characteristics of the infants in the two groups and of their mothers were similar (Table 1) . A total of 92 percent of the infants were given at least two doses of either indomethacin or placebo, and the infants in each group received an identical mean (±SD) total dose of study drug that was equivalent to 0.27±0.07 mg of indomethacin per kilogram. The number of doses received, the reasons for withholding one or more doses, and the age of the infants at the time the first dose was administered are shown in Table 2 .
Primary Outcome at a Corrected Age of 18 Months
Adequate data for an analysis of the composite primary outcome were available for 1143 of the infants who were enrolled in the study (95 percent). Indomethacin prophylaxis did not improve the rate of survival without neurosensory impairment (Table 3) . Adjustments for prespecified and prognostically important base-line characteristics (presence or absence of antenatal administration of glucocorticoids, mother's educational level, infant's gestational age, and presence or absence of a multiple birth) yielded the same odds ratio. There was also little evidence that indomethacin prophylaxis altered the rates of any of the individual components of the primary outcome ( Fig.  2 and Table 3 ). The mean (±SD) Mental Development Index score was 83±18 in the indomethacin group and 84±18 in the placebo group. The median age at follow-up was 18. 
Secondary Outcomes
Among the survivors, the incidence rates of hydrocephalus requiring the placement of a shunt, seizure disorder, and microcephaly were not affected by the administration of indomethacin (Table 4) . Indomethacin prophylaxis reduced the incidence of patent ductus arteriosus. Consistent with this reduction, the need for drug or surgical therapy to close the duct was also reduced in the infants in the indomethacin group (Table 4) .
Although the rates of periventricular and intraventricular hemorrhage were identical in the two treatment groups, the risk of grade 3 or grade 4 hemorrhages was lower in the indomethacin group (Table 4) . However, the incidence of any type of lesion indicative of injury to the cerebral white matter was similar in the two groups, as was the incidence of all other secondary short-term outcomes (Table 4 ).
DISCUSSION
We found that the use of indomethacin prophylaxis to reduce the incidence of patent ductus arteriosus and of severe periventricular and intraventricular hemorrhage in extremely-low-birth-weight infants did not improve the rate of survival without neurosensory impairment at a corrected age of 18 months. Also, indomethacin prophylaxis did not reduce the incidence of any of the individual events included in the composite primary outcome in this trial. Moreover, it is unlikely that indomethacin prophylaxis will be beneficial in the smallest infants, since we found no differential treatment effect in an analysis stratified according to birth weight.
It is unlikely that we missed a clinically important long-term effect of indomethacin. A post hoc calculation confirmed that we would have been able to detect a 20 percent reduction in risk, had it existed, with a power of 90 percent, and we think that our estimate of the long-term effects of indomethacin prophylaxis is unbiased. The investigators and anyone *Plus-minus values are means ±SD. †The 10th percentile for gestational age in a normal population was as reported by Arbuckle involved in the care or follow-up of the infants in the study remained unaware of the treatment-group assignments throughout the trial, and ascertainment of the primary outcome toward the end of the second year of life was nearly complete. This is important because preterm infants who are followed up with ease may not have the same outcomes as those who are followed up with difficulty. 15 In this trial, only 13 children were entirely lost to follow-up, and the analysis of the primary outcome was based on results from 95 percent of all the infants who had been assigned to a treatment group. *Odds ratios have been adjusted for the birth-weight stratum and center, except for the odds ratios for hearing loss and bilateral blindness, which were adjusted only for the birth-weight stratum. P values are for the adjusted odds ratios. CI denotes confidence interval, and MDI Mental Development Index. †These data do not include the 13 infants who were lost to follow-up at 18 months. ‡Data for this outcome exclude infants who died before scheduled tests and those who were alive but were not tested or were lost to follow-up. Information about the long-term effects of indomethacin prophylaxis has been derived primarily from a trial by Ment et al. 16 In that study, indomethacin prophylaxis also failed to reduce the rates of cerebral palsy, deafness, and blindness. 17, 18 However, Ment et al. reported a favorable effect of indomethacin prophylaxis on cognitive function in a subgroup of children who spoke English as their only language at 4.5 years of age. 18 Our trial, however, was designed to test different hypotheses from those of the trial by Ment et al., and we had different criteria for enrollment, different primary end points, and different rates of follow-up. For example, we did not exclude infants with preexisting periventricular or intraventricular hemorrhage. Our relatively unrestrictive criteria for eligibility should increase the generalizability of our results. 19 We administered the Bayley Scales of Infant Development II at a corrected age of 18 months and found that more than one quarter of all the surviving infants had moderate-to-severe cognitive delays, defined as a Mental Development Index score of less than 70. Although this finding is alarming, it is consistent with those of two recent studies that used the same scales to measure the cognitive function of extremely-low-birth-weight infants at a corrected age of 18 months and of 30 months, respectively. 20, 21 The validity of the Mental Development Index score at this age as a predictor of later intellectual functioning remains to be determined. However, we doubt that extended follow-up will uncover substantial benefits of prophylaxis with indomethacin.
In our trial, indomethacin did not reduce the incidence of lesions that may signify white-matter injury, although it did reduce the incidence of severe periventricular and intraventricular hemorrhage. Why, then, did this reduction not translate into a better long-term outcome? Severe hemorrhage was associ-*Odds ratios have been adjusted for the birth-weight stratum and center, except for the odds ratios for hydrocephalus, seizure disorder, microcephaly, and need for oxygen at discharge to home, which have been adjusted only for the birthweight stratum. P values are for the adjusted odds ratios. CI denotes confidence interval. †Data for this outcome exclude infants who died before scheduled tests and those who were alive but were not tested or were lost to follow-up. ‡A total of 103 infants in the indomethacin group and 96 in the placebo group died before a postmenstrual age of 36 weeks. In two infants in each group the need for supplemental oxygen at this age was unknown. §A total of 110 infants in the indomethacin group and 100 in the placebo group died before discharge to home. In four infants in the indomethacin group and five in the placebo group the need for supplemental oxygen at discharge to home was unknown. ated with a poor outcome, but the incidence of severe hemorrhage was quite low, and the absolute reduction in incidence associated with indomethacin prophylaxis was small (4 percentage points). This reduction in the incidence of severe hemorrhage would account for an absolute reduction of only 1.6 percent in the primary outcome. On the basis of the previously documented shortterm benefits, many clinicians have adopted a policy of administering indomethacin prophylaxis in verylow-birth-weight infants, although others have remained skeptical of this approach. 2 What are the implications of our findings for the care of very preterm infants? Indomethacin prophylaxis reduces the need for medical and surgical closure of the ductus arteriosus. Approximately 20 infants must receive indomethacin prophylaxis to avert one operation. 22 Our results suggest that closure of the ductus with the prophylactic administration of indomethacin can be achieved without serious adverse effects on outcomes such as necrotizing enterocolitis or retinopathy. However, indomethacin prophylaxis should not be prescribed with the expectation that the chances of survival without neurosensory impairment will be improved. We must look elsewhere in our quest to reduce the high rates of adverse outcomes in extremely-low-birth-weight infants. 
